Fleury (FLRY3) Stock Overview

Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It provides laboratory and imaging tests, genomics, health management and platform, diagnostic information, check-up and reference laboratory, clinic day, infusion center, orthopedics and ophthalmology, dental imaging tests, and diagnostic imaging services. The company also offers Saúde I, a digital healthcare platform that provides services, including scheduling and performing teleconsultations, and face-to-face consultations, as well as scheduling and accessing diagnostic test results, electronic medical record, and self-manage health issues. It operates customer service units and hospital-based units under the Fleury, Felippe Mattoso, Labs a+, Diagnoson a+, Papaiz, Serdil, LAFE, Instituto de Radiologia de Natal, Centro de Patologia Clínica, Diagmax, Santécorp, a+SP, CIP, Saha, Moacir Cunha, Vita, e Campana, Methodos, Pretti, Bioclinico, a+PE, Marcelo Magalhaes, Inlab, Weinmann, a+, a+BA, IRN, CPC, and a+PI brand names. The company was founded in 1926 and is headquartered in São Paulo, Brazil.